DPP4 and Hypoglycemia: These include more comprehensive patient education, the earlier use of insulin while significant β-cell function is still preserved, which is associated with a lower risk of hypoglycemia [23], and the earlier use of basal insulin in combination with oral agents, including DPP-4 inhibitors and GLP-1 agonists, which have a low risk of inducing hypoglycemia.